Thermo Fisher Scientific Bolsters North America OSD Capabilities to Enhance Drug Development

Thermo Fisher Scientific is making a significant leap in enhancing its oral solid dose capabilities with a $22-million investment in its Cincinnati, Ohio, and Bend, Oregon facilities. This move aims to strengthen R&D, manufacturing, and testing capabilities, ultimately accelerating drug development for biotech and pharmaceutical companies.

Oral solid dose formulations are the most prescribed dosage forms worldwide, representing 84% of all medications due to their storage stability and ease of use. Recognizing the increasing demand for small molecule OSD solutions, Thermo Fisher has doubled the site’s footprint and added flexible R&D space in Cincinnati. These expansions will enable rapid project initiation and leverage next-generation technologies for data-informed decision-making, addressing early development challenges.

The facility upgrade enhances capabilities in R&D manufacturing and testing, focusing on solubility and bioavailability enhancement solutions crucial for accelerating pre-clinical oral drug product development. Cincinnati’s new flexible space supports early-stage development, mitigating risks of costly trial-and-error cycles.

With over 30 years of expertise in OSD formulations, Thermo Fisher’s substantial investment underscores its commitment to helping clients navigate regulatory landscapes and overcome formulation challenges. This expansion builds on their global footprint, which includes facilities in France, Puerto Rico, Canada, and North Carolina. By supporting over 125 new drug approvals in the past decade, Thermo Fisher is a pivotal player in making life-saving therapies more accessible.

For the latest updates and in-depth insights into the world of Science, including new investments, industry trends, and regulatory news, contact Amy Pearce today!